Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093613 · ClinicalTrials.gov registry record · Phase 1
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00093613: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00093613 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093613, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.
Interventions
- OTHER pharmacological study
- DRUG sorafenib tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2004-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093613
The ClinicalTrials.gov registry entry for NCT00093613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.
NCT00093613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093613 about?
NCT00093613 is a clinical study titled "Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma". This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.
What is the current status of trial NCT00093613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2004-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00093613?
The interventions under investigation include: pharmacological study (OTHER), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00093613?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.